香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 於2025年9月15日，本公司根據2024年股份獎勵計劃之條款向17名承授人授出合 共949,000個受限制股份單位，惟須待接納後方可作實。 本公告乃根據上市規則第17.06A、17.06B及17.06C條作出。 受限制股份單位 本公告僅供參考之用，並不構成收購、購買或認購阿里健康信息技術有限公司股份 的邀請或要約。 ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 （於百慕達註冊成立之有限公司） （股份代號：00241） 授出受限制股份單位 授出受限制股份單位 於2025年9月15日，本公司根據2024年股份獎勵計劃之條款向17名承授人授出合共 949,000個受限制股份單位，惟須待接納後方可作實。授出受限制股份單位之詳情 如下： 授出日期 ： 2025年9月15日 承授人 ： 向承授人授出合共949,000個受限制股份單位，彼等為本 ...

9月9日，港股互联网医疗概念板块一骑绝尘，成为当日市场的领涨先锋。 板块内，个股涨势喜人。截至发稿前，叮当健康（09886.HK）涨9.76%，阿里健康（00241.HK）大涨9.40%，京东健康（06618.HK）、平安好医生 （01833.HK）也都加入这股上涨浪潮，涨幅分别为6.58%、3.39%。 | 序号 | 財華社 FINET 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | --- | | 1 | 09886 | 叮当健康 | (0) 0.900 | +0.080 | 9.76% | | 2 | 00241 | 阿里健康 | 7.100 | +0.610 | 9.40% | | 3 | 06618 | 京东健康 | 1 67.200 | +4.150 | 6.58% | | 4 | 01833 | 平安好医生 | 11 21.940 | +0.720 | 3.39% | | 5 | 06060 | 众安在线 | 18.450 | +0.040 | 0.22% | | 6 | 02159 | 麦迪 康 | 1.490 | 0 ...

Group 1 - Alibaba Health (00241) shares increased by 10%, reaching a high of 7.18 HKD, the highest since January 2023, with a trading volume of 2.036 billion HKD [1] - HSBC Global Research anticipates that health products will continue to be the fastest-growing category for Alibaba Health, supported by its strong platform ecosystem [1] - The focus on first-party sales (1P) profitability may limit sales growth for pharmaceuticals, but the shift of offline traffic to online due to tightened social insurance claims is expected to benefit Alibaba Health from strong demand for innovative drugs [1] Group 2 - The sales momentum of innovative drugs exceeding expectations may provide upward potential for revenue and net profit forecasts [1] - The National Medical Products Administration is drafting a compliance guideline for online retail of prescription drugs to enhance compliance awareness and capabilities among stakeholders [1] - The guideline emphasizes that companies must fulfill their responsibilities for drug safety and continuously improve their quality management systems and compliance management [1]

Group 1 - Alibaba Health (00241) shares increased by 10%, reaching a high of 7.18 HKD, the highest since January 2023, with a trading volume of 2.036 billion HKD [1] - HSBC Global Research anticipates that health products will continue to be the fastest-growing category for Alibaba Health, supported by its robust platform ecosystem [1] - The focus on first-party sales (1P) profitability may limit sales growth in pharmaceuticals, but the shift of offline traffic to online due to tighter social insurance claims is expected to benefit Alibaba Health from strong demand for innovative drugs [1] Group 2 - The unexpected sales momentum of innovative drugs may provide upward potential for revenue and net profit forecasts for Alibaba Health [1] - The National Medical Products Administration is drafting a compliance guideline for online prescription drug sales to enhance compliance awareness and capabilities among stakeholders [1] - The guideline emphasizes that companies must fulfill their responsibilities for drug safety and continuously improve their quality management systems and compliance management [1]

Group 1 - The Hang Seng Index rose by 0.80%, the Hang Seng Tech Index increased by 1.03%, and the Hang Seng China Enterprises Index strengthened by 0.90% during the midday session, with a market turnover of HKD 159.68 billion [1] - The southbound capital has become a stabilizer for the Hong Kong stock market, with a cumulative net inflow exceeding HKD 100 billion since the beginning of the year, particularly benefiting sectors such as commerce and retail, telecommunications, electronics, media, and computer technology [1] - The current interest rate cut cycle by the Federal Reserve is attracting more global allocation funds to the Hong Kong stock market, with historical data indicating that the Hong Kong stock market performs well during preventive interest rate cut cycles [1] Group 2 - The Hong Kong Stock Connect Technology ETF (159101) closely tracks the CSI Hong Kong Stock Connect Technology Index, covering major tech leaders such as Xiaomi, Tencent, Alibaba, Meituan, BYD, SMIC, and BeiGene, with the top five constituents accounting for 57% of the weight [2] - The ETF supports T+0 trading and does not occupy QDII quotas, allowing investors to flexibly apply allocation strategies based on their needs, such as using it as a core holding for growth assets or capturing market trends with high elasticity [2] - The ETF provides a one-stop solution for "software + hardware + new consumption + innovative drugs + new energy vehicles," making it suitable for long-term investors, trend investors, and those looking to smooth risks through dollar-cost averaging [2]

Core Viewpoint - Alibaba Health is experiencing significant stock price growth, attributed to its robust platform ecosystem and strong sales performance in health products and innovative drugs [1] Group 1: Financial Performance - Alibaba Health's stock rose by 6.32% to HKD 6.9, with a trading volume of HKD 1.099 billion [1] - HSBC Global Research has revised its revenue growth forecast for Alibaba Health for FY2026 from 9% to 15%, indicating improved profit margins due to a shift in revenue structure towards non-pharmaceuticals and enhanced profitability in first-party sales [1] - Citi has raised Alibaba Health's FY2026 revenue growth guidance to 10%-20% from the previous 5%-10%, and adjusted net profit growth guidance to 20%-30% from 10%-20%, driven by better-than-expected sales of original and innovative drugs, particularly GLP-1 medications [1] Group 2: Market Trends - The strong sales data from Alibaba Health and JD Health confirm the accelerating and sustainable trend of prescription drug outflow [1] - As original and innovative pharmaceutical companies expand new sales channels, online platforms like Alibaba Health and JD Health are positioned as the primary beneficiaries [1]

汇丰环球研究报告指出，得益于其强大的平台生态系统，预期保健品将继续成为阿里健康增长最快的品 类。对于药品，虽然公司持续聚焦于第一方销售(1P)盈利能力可能限制销售增长，但该行认为随着社会 保险理赔收紧，线下流量转向线上，阿里健康将受益于创新药品的强劲需求。结合强劲的广告势头，该 行将阿里健康2026财年收入增长预测，从之前的年增9%，上调至年增15%，利润率因收入结构向非药 品转移及1P利润率提升而有改善空间，公司2026财年净利润增长可超越收入增长。 里昂指出，阿里健康将2026财年收入增长指引上调到10%至20%(原为5%至10%)，并将调整后净利润增 长指引上调到20%至30%(原为10%至20%)，主因原研与创新药(尤其是GLP-1药物)销售表现优于预期。 阿里健康与京东健康的强劲销售数据，证实处方药外流趋势加速且具可持续性。随着原研与创新药企拓 展新销售渠道，线上平台阿里健康与京东健康成为最大受益者。 智通财经APP获悉，阿里健康(00241)午前涨超6%，截至发稿，涨6.32%，报6.9港元，成交额10.99亿港 元。 ...

消息上，9月8日，据"国家药监局"微信公众号消息，为贯彻落实《药品网络销售监督管理办法》，进一 步增强药品网络销售相关方合规意识和能力，规范处方药网络零售行为，国家药监局组织起草了《处方 药网络零售合规指南》，现向社会公开征求意见。 港股互联网医疗股普遍上涨，其中，阿里健康涨超6%，叮当健康涨近5%，京东健康涨3%，平安好医生 涨2.5%，众安在线涨1.6%。 有分析指出，对互联网医疗行业而言，是继《药品网络销售监督管理办法》之后又一重大的长期利好信 号。它不仅仅是利好，更意味着行业进入了 "精细化管理、高质量发展" 的新阶段。头部平台（如京东 健康、阿里健康、平安好医生等）在IT系统建设、合规团队、与监管沟通等方面拥有绝对优势，能更 快、更好地适应新规则。(格隆汇) | 代码 | 名称 | | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | --- | | 00241 | 阿里健康 | 0 | 6.890 | 6.16% | | 09886 | 叮当健康 | | 0.860 | 4.88% | | 06618 | 京东健康 | | 64.950 | 3.01% | | 018 ...

Core Viewpoint - The Chinese internet ETF (159607) has shown a positive trend with a 1.12% increase, marking three consecutive days of gains, driven by strong performances from key stocks like Alibaba Health and NetEase [1][3]. Group 1: ETF Performance - The Chinese internet ETF has a recent trading volume of 8.2%, with a total transaction value of 87.37 million yuan [3]. - Over the past year, the average daily trading volume of the ETF is 364 million yuan, and its latest scale has reached 1.031 billion yuan [3]. - The net value of the ETF has increased by 53.64% over the past year, with the highest monthly return since inception being 40.52% [3]. Group 2: Stock Performance - Key stocks within the ETF include Alibaba-W, which rose by 2.91%, and NetEase-S, which increased by 4.01% [4]. - The top ten weighted stocks in the CSI Overseas China Internet 30 Index include Tencent, Alibaba-W, and Xiaomi, collectively accounting for 85.54% of the index [6]. Group 3: Market Conditions - Recent U.S. employment data indicates a significant shortfall in job growth, with only 22,000 jobs added in August, compared to an expected 75,000 [3]. - The U.S. unemployment rate has reached 4.3%, the highest since the end of 2021, leading to a 100% probability of a Federal Reserve rate cut in September [3]. - Factors such as potential Fed rate cuts and adjustments in U.S. Treasury durations may enhance the attractiveness of Asian currencies, particularly the renminbi, to foreign investors in the Hong Kong market [3].

Group 1 - Hikvision announced a mid-term dividend plan, proposing a cash dividend of 4.00 RMB per 10 shares (including tax), with no stock bonus or capital reserve conversion [1] - The total cash dividend amount is expected to be 3.666 billion RMB, accounting for approximately 64.80% of the company's net profit attributable to shareholders for the first half of 2025 [1] - The mid-term dividend plan requires approval from the company's shareholders' meeting, indicating some uncertainty regarding its implementation [2] Group 2 - In the first half of the year, the company achieved total operating revenue of 41.818 billion RMB, representing a year-on-year growth of 1.48% [4] - The net profit attributable to shareholders for the same period was 5.657 billion RMB, showing a year-on-year increase of 11.71% [4]